| Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas BJ Sworder, DM Kurtz, SK Alig, MJ Frank, N Shukla, A Garofalo, ... Cancer Cell 41 (1), 210-225. e5, 2023 | 51 | 2023 |
| Unmet needs in the evaluation, treatment, and recovery for 167 children affected by acute flaccid myelitis reported by parents through social media R Bove, W Rowles, M Carleton, E Olivera, M Sheehan, HP Werdal, ... Pediatric Neurology 102, 20-27, 2020 | 22 | 2020 |
| Experiences of sexual and gender minority people living with multiple sclerosis in Northern California: An exploratory study A Anderson, J Dierkhising, G Rush, M Carleton, N Rosendale, R Bove Multiple sclerosis and related disorders 55, 103214, 2021 | 11 | 2021 |
| A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial R Bove, A Anderson, W Rowles, KA Rankin, NK Hills, M Carleton, ... Multiple sclerosis and related disorders 61, 103747, 2022 | 7 | 2022 |
| Small survivors: unexpected endemic diversity of Hyposmocoma (Lepidoptera: Cosmopterigidae) moths on Kahoʻolawe, a degraded Hawaiian island MJ Medeiros, WP Haines, MA Carleton, D Rubinoff Zoological Journal of the Linnean Society 180 (3), 570-592, 2017 | 3 | 2017 |
| Optimizing a center's post-marketing experience with an infusible treatment: ocrelizumab for MS L Law, T Lin, L Do, S Merrill, R Rodriguez-Monguio, T Krishnakumar, ... MULTIPLE SCLEROSIS JOURNAL 25, 783-783, 2019 | 1 | 2019 |
| 160 Circulating tumor DNA for measurable residual disease (MRD) detection in multiple myeloma patients undergoing CAR T-cell therapy H Hosoya, M Carleton, K Tanaka, B Sworder, V Hovanky, G Duran, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| COMPARATIVE ACCURACY OF ALTERNATIVE EARLY MEASURES OF RESIDUAL DISEASE AFTER CAR19 THERAPY OF RELAPSED/REFRACTORY LBCL BJ Sworder, SK Alig, N Shukla, A Garofalo, CW Macaulay, MS Esfahani, ... Hematological Oncology 41, 214-216, 2023 | | 2023 |
| Tumor and immune determinants of response to anti-BCMA CAR T-cell therapy in multiple myeloma using cell-free DNA M Carleton, H Hosoya, KL Tanaka, B Sworder, V Hovanky, B Sahaf, ... Cancer Research 83 (7_Supplement), 5707-5707, 2023 | | 2023 |
| Circulating Tumor DNA for Disease Characterization and Response Prediction in Myeloma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy H Hosoya, M Carleton, K Tanaka, B Sworder, V Hovanky, GE Duran, ... 2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023 | | 2023 |
| Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA H Hosoya, M Carleton, KL Tanaka, B Sworder, V Hovanky, GE Duran, ... Blood 140 (Supplement 1), 1546-1548, 2022 | | 2022 |
| Hormonal Therapy For Menopausal Women With MS: A Phase II RCT A Anderson, W Rowles, G Rush, M Carleton, N Hills, J Cooper, BA Cree, ... MULTIPLE SCLEROSIS JOURNAL 26 (1_ SUPPL), 45-45, 2020 | | 2020 |
| Strengthening knowledge when data are scarce: the role of social media after AFM.(P5. 6-066) R Bove, M Carleton Neurology 92 (15 Supplement), 2019 | | 2019 |
| Small survivors: Unexpected diversity of Hyposmocoma (Lepidoptera: Cosmopterigidae) moths on a pummeled Hawaiian island MJ Medeiros, WP Haines, M Carleton, D Rubinoff 2016 International Congress of Entomology, 2016 | | 2016 |
